Albiges L, Powles T, Staehler M, Bensalah K, Giles RH, Hora M, et al. Updated European Association of Urology Guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur Urol. 2019;76:151–6.

Article  PubMed  Google Scholar 

Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20:1370–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kato R, Obara W. Persisting challenges in the development of predictive biomarkers for immuno-oncology therapies for renal cell carcinoma. Expert Rev Anticancer Ther. 2025;25:97–103.

Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155–64.

Article  CAS  PubMed  Google Scholar 

Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017;18:611–22.

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33:1430–7.

Article  CAS  PubMed  Google Scholar 

Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J Clin Oncol. 2017;35:3851–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leven C, Padelli M, Carré JL, Bellissant E, Misery L. Immune checkpoint inhibitors in melanoma: a review of pharmacokinetics and exposure–response relationships. Clin Pharmacokinet. 2019;58:1393–405.

Article  PubMed  Google Scholar 

Liu C, Yu J, Li H, Liu J, Xu Y, Song P, et al. Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis. Clin Pharmacol Ther. 2017;101:657–66.

Article  CAS  PubMed  Google Scholar 

Sanghavi K, Zhang J, Zhao X, Feng Y, Statkevich P, Sheng J, et al. Population pharmacokinetics of ipilimumab in combination with nivolumab in patients with advanced solid tumors. CPT Pharmacometrics Syst Pharmacol. 2020;9:29–39.

Article  CAS  PubMed  Google Scholar 

Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y. Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacometrics Syst Pharmacol. 2017;6:58–66.

Article  CAS  PubMed  Google Scholar 

Maritaz C, Combarel D, Dalban C, Blondel L, Broutin S, Marabelle A, et al. Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma. J Immunother Cancer. 2025;13:e010059.

Article  PubMed  PubMed Central  Google Scholar 

Feng Y, Wang X, Bajaj G, Agrawal S, Bello A, Lestini B, et al. Nivolumab exposure-response analyses of efficacy and safety in previously treated squamous or nonsquamous non-small cell lung cancer. Clin Cancer Res. 2017;23:5394–405.

Article  CAS  PubMed  Google Scholar 

Bellesoeur A, Ollier E, Allard M, Hirsch L, Boudou-Rouquette P, Arrondeau J, et al. Is there an exposure-response relationship for nivolumab in real-world NSCLC patients? Cancers. 2019;11:1784.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hurkmans DP, Basak EA, van Dijk T, Mercieca D, Schreurs MWJ, Wijkhuijs AJM, et al. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. J Immunother Cancer. 2019;7:192.

Article  PubMed  PubMed Central  Google Scholar 

Basak EA, Koolen SLW, Hurkmans DP, Schreurs MWJ, Bins S, Oomen De Hoop E, et al. Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer. Eur J Cancer. 2019;109:12–20.

Wang X, Feng Y, Bajaj G, Gupta M, Agrawal S, Yang A, et al. Quantitative characterization of the exposure-response relationship for cancer immunotherapy: a case study of nivolumab in patients with advanced melanoma. CPT Pharmacometrics Syst Pharmacol. 2017;6:40–8.

Article  PubMed  Google Scholar 

Zhao Y, Tsujimoto A, Ide T, Zhang J, Feng Y, Gao L, et al. Model-based population pharmacokinetic and exposure response analyses for safety and efficacy of nivolumab as adjuvant treatment in subjects with resected oesophageal or gastroesophageal junction cancer. Br J Clin Pharmacol. 2024;90:2920–30.

Article  CAS  PubMed  Google Scholar 

Agrawal S, Feng Y, Roy A, Kollia G, Lestini B. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer. 2016;4:72.

Article  PubMed  PubMed Central  Google Scholar 

Sangro B, Yau T, El-Khoueiry AB, Kudo M, Shen Y, Tschaika M, et al. Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040). Clin Transl Sci. 2023;16:1445–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koguchi Y, Iwamoto N, Shimada T, Chang SC, Cha J, Curti BD, et al. Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab. J Immunother Cancer. 2021;9:e002663.

Article  PubMed  PubMed Central  Google Scholar 

Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res. 2013;19:3977–86.

Article  CAS  PubMed  Google Scholar 

Vano YA, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, et al. Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncol. 2022;23:612–24.

Article  CAS  PubMed  Google Scholar 

Marin C, Khoudour N, Millet A, Lebert D, Bros P, Thomas F, et al. Cross-validation of a multiplex LC-MS/MS method for assaying mAbs plasma levels in patients with cancer: a GPCO-UNICANCER study. Pharmaceuticals. 2021;14:796.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Millet A, Khoudour N, Bros P, Lebert D, Picard G, Machon C, et al. Quantification of nivolumab in human plasma by LC-MS/HRMS and LC-MS/MS, comparison with ELISA. Talanta. 2021;224:121889.

Article  CAS  PubMed  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

Article  CAS  PubMed  Google Scholar 

Abe K, Shibata K, Naito T, Otsuka A, Karayama M, Maekawa M, et al. Impacts of cachexia progression in addition to serum IgG and blood lymphocytes on serum nivolumab in advanced cancer patients. Eur J Clin Pharmacol. 2022;78:77–87.

Article  CAS  PubMed  Google Scholar 

Aslan V, Kılıç ACK, Sütcüoğlu O, Eraslan E, Bayrak A, Öksüzoğlu B, et al. Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma. Urol Oncol. 2022;40:494.e1–494.e10.

Article  CAS  PubMed  Google Scholar 

Otten LS, Piet B, van den Haak D, Schouten RD, Schuurbiers M, Badrising SK, et al. Prognostic value of nivolumab clearance in non-small cell lung cancer patients for survival early in treatment. Clin Pharmacokinet. 2023;62:1749–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gravis G, Marino P, Olive D, Penault-LLorca F, Delord JP, Simon C, et al. A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study. BMC Cancer. 2023;23:393.

Article  CAS  PubMed  PubMed Central